威尼斯人
阿扎胞苷
癸他滨
医学
中性粒细胞减少症
发热性中性粒细胞减少症
内科学
髓系白血病
肿瘤科
低甲基化剂
白细胞减少症
化疗
胃肠病学
白血病
基因表达
化学
DNA甲基化
基因
慢性淋巴细胞白血病
生物化学
作者
Daniel A. Pollyea,Keith W. Pratz,Anthony Letaï,Brian A. Jonas,Andrew H. Wei,Vinod Pullarkat,Marina Konopleva,Michael J. Thirman,Martha Arellano,Pamela S. Becker,Brenda Chyla,Wan Jen Hong,Qi Jiang,Jalaja Potluri,Courtney D. DiNardo
摘要
Abstract This analysis represents the longest‐term follow‐up for patients with acute myeloid leukemia (AML) treated with 400 mg of venetoclax plus azacitidine or decitabine. Adults with newly diagnosed AML ineligible for intensive chemotherapy were enrolled in an open‐label, non‐randomized, multicenter phase 1b trial of venetoclax with azacitidine (AZA; 75 mg/m 2 ; days 1‐7) or decitabine (DEC; 20 mg/m 2 ; days 1‐5). Endpoints included safety, response rates (complete remission [CR], CR with incomplete blood count recovery [CRi]), response duration and overall survival (OS). The median follow‐up time was 29 and 40 months for patients treated with venetoclax plus AZA and DEC combinations, respectively. Key Grade ≥ 3 AEs (AZA and DEC) were febrile neutropenia (39% and 65%), anemia (30% and 26%), thrombocytopenia (25% and 23%), and neutropenia (20% and 10%). The CR/CRi rate was 71% for venetoclax plus AZA and 74% for venetoclax plus DEC. The median duration of CR/CRi was 21.9 months and 15.0 months, and the median OS was 16.4 months and 16.2 months, for venetoclax plus AZA and DEC, respectively. These results support venetoclax plus hypomethylating agents as highly effective frontline AML therapies for patients unfit for intensive chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI